In 2023, diabetes medicine sales in Türkiye reached 6.49 Billion New Turkish Liras (TRY). Since then, sales have been forecasted to grow annually: reaching 7.38 Billion TRY in 2024, 8.27 Billion TRY in 2025, 9.16 Billion TRY in 2026, 10.03 Billion TRY in 2027, and 10.9 Billion TRY in 2028. Year-on-year variations show substantial growth: 13.7% from 2023 to 2024, 12.1% from 2024 to 2025, 10.8% from 2025 to 2026, 9.6% from 2026 to 2027, and 8.7% from 2027 to 2028. The Compound Annual Growth Rate (CAGR) for the period 2024-2028 is approximately 10.9%.
Future trends to watch for include advancements in diabetes treatment technologies, the impact of government healthcare policies, and the increasing prevalence of diabetes due to lifestyle changes. Additionally, increased healthcare coverage and pharmaceutical innovations are likely to drive further market growth.
